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OBJECTIVES The purpose of this study was to target acoustically reflective liposomes to atherosclerotic
plaques in vivo for ultrasound image enhancement.
BACKGROUND We have previously demonstrated the development of acoustically reflective liposomes that
can be conjugated for site-specific acoustic enhancement. This study evaluates the ability of
liposomes coupled to antibodies specific for different components of atherosclerotic plaques
and thrombi to target and enhance ultrasonic images in vivo.
METHODS Liposomes were prepared with phospholipids and cholesterol using a dehydration/
rehydration method. Antibodies were thiolated for liposome conjugation with
N-succinimidyl 3-(2-pyridyldithio) propionate resulting in a thioether linkage between the
protein and the phospholipid. Liposomes were conjugated to antifibrinogen or anti–
intercellular adhesion molecule-1 (anti–ICAM-1). In a Yucatan miniswine model, athero-
sclerosis was developed by crush injury of one carotid and one femoral artery and ingestion of
a hypercholesterolemic diet. After full plaque development the arteries were imaged
(20-MHz intravascular ultrasound catheter and 7.5-MHz transvascular linear probe) after
injection of saline, unconjugated liposomes and antibody conjugated liposomes.
RESULTS Conjugated liposomes retained their acoustically reflective properties and provided ultrasonic
image enhancement of their targeted structures. Liposomes conjugated to antifibrinogen
attached to thrombi and fibrous portions of the atheroma, whereas liposomes conjugated to
anti–ICAM-1 attached to early atheroma.
CONCLUSIONS Our data demonstrate that this novel acoustic agent can provide varying targeting with
different antibodies with retention of intravascular and transvascular acoustic properties.
(J Am Coll Cardiol 1999;33:867–75) © 1999 by the American College of Cardiology
Atherosclerosis (ATH) has been shown to be extensive, of
variable morphology and widely distributed in vascular beds
due to variable effects of remodeling, luminal and neural
influences (1–5). High resolution ultrasound, both external
ultrasound for the carotid, femoral and superficial arteries,
and intravascular ultrasound for the coronaries, iliacs and
aortas, has been helpful in identifying atheroma location
and severity (6–10). However, there continues to be diffi-
culty in identifying surface characteristics of plaque and
plaque morphology. Investigators have been able to utilize
ultrasound tissue characterization to distinguish calcified
lesions, but have had lesser degrees of success with fibrous,
fibrofatty, fatty and thrombotic lesions (11–15). An agent
that has the potential to highlight surface features of the
arterial wall and atheroma as well as highlight atheroma
components would have far-reaching implications for more
accurate morphologic identification, quantitation of and
direction of therapy toward plaque components in different
stages of development.
We have previously demonstrated the generation of
acoustically reflective liposomes, solely by controlling the
lipid composition and method of production (16). These
acoustic liposomes consist of a 60:8:2:30 molar mixture of
phosphatidylcholine:phosphatidylethanolamine: phosphati-
dylglycerol:cholesterol and are prepared by a dehydration/
rehydration method. Freeze fracture electron microscopy
has illustrated that highly acoustic liposomes are multila-
mellar, with well separated bilayers and internal vesicles,
whereas nonacoustic liposomes consist of one thick outer
membrane. With no gas entrapment and a mean size of less
than 1 mm, the liposomes will be stable in circulation and
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easily pass through pulmonary capillaries. The liposomes
retain their acoustic properties at 37°C, in the presence of
blood and after conjugation to antibodies. Labeling the
liposomes with antibodies results in the formation of a
site-specific contrast agent that can enhance ultrasound
images of chosen target tissues and molecules. When
conjugated to antifibrinogen antibodies, the acoustic lipo-
somes can target to fibrin-coated surfaces and thrombi in
vitro (17). Scanning electron microscopy and ultrasound
imaging revealed that antifibrinogen liposomes remain at-
tached to their target sites after saline wash, whereas
unconjugated liposomes and liposomes conjugated to a
nonspecific antibody did not.
Atherosclerotic plaque formation involves a complex
interplay between the vascular wall and blood components.
Early in plaque formation different molecules are involved in
the recruitment of a variety of cells to the lesion. Intercel-
lular adhesion molecule-1 (ICAM-1) is expressed on the
endothelium and enhances the recruitment of monocytes to
the plaque (18,19). Staining of ICAM-1 has shown dra-
matic enhancement of expression on endothelial cells in
fatty streaks and fibrofatty lesions and little expression in
fibrous lesions and none in normal arteries (18). Liposomes
conjugated to anti–ICAM-1 were used to target early stage
atherosclerotic plaques.
This study describes acoustically reflective liposomes,
conjugated to antifibrinogen and anti–ICAM-1, that can
target atherosclerotic plaques and thrombi in a miniswine




Liposomes were made from L-alpha phosphatidylcholine
Type XIII-E (PC), 3-(2-pyridyldithiolpropionic acid
N-hydroxysuccinimide ester (SPDP) and cholesterol (Sig-
ma Chemical Co., St. Louis, Missouri); maleimido-4 (p-
phenylbutyrate)-phosphatidylethanolamine (MPB-PE)
(Avanti Polar Lipids, Alabaster, AL); 1,2-dipalmitoyl-sn-
glycero-3-phosphoglycerol (DPPG) (Fine Chemicals,
Liestal, Switzerland); dithiothreitol (DTT) (Fisher Scien-
tific, Itasca, IL); rabbit antihuman fibrinogen (American
Diagnostica, Greenwich, CT), and intercellular adhesion
molecule antibodies.
Preparation of Antibody Conjugated Liposomes
Preparation of vesicles. Maleimido-4 (p-phenylbutyrate)-
phosphatidylethanolamine, a maleimide-containing phos-
pholipid, was included in the composition of the liposomes
for conjugation to the antibodies. The maleimide group of
MPB-PE reacts with thiol groups, forming a stable
thioether bridge (20). A 60:8:2:30 molar mixture of PC,
MPB-PE, DPPG and cholesterol was dissolved in chloro-
form. The solvent was evaporated by a rotary evaporator
(Labconco, Kansas City, MO), rotated at 120 rpm and
immersed in a thermostatted water bath, with the temper-
ature set at 50°C under argon. The resulting lipid film was
then placed in a dessicator under vacuum for 2 days for
complete drying. The dry lipid film was rehydrated with
deionized water to give a concentration of 10 mg lipid/1 ml
water. After removing the film from the walls of the flask,
the dispersion was sonicated in a water bath sonicator
(Fisher Scientific, Itasca, IL) until the mean size of the
liposomes was approximately 500 nm. Liposome size was
determined by quasielastic light scatter as described below.
D-mannitol (0.2 mol/L) was added to the liposome suspen-
sion in a 1:1 vol/vol ratio, and this suspension was frozen
overnight at 270°C. The frozen samples were placed in a
lyophilizer (Labconco, Kansas City, MO) for 2 days. The
dried lipids were then resuspended with 0.1 mol/L phos-
phate buffer, pH 7.4, to give a concentration of 10 mg
lipid/1 ml buffer. After hand shaking and brief vortexing,
the size of the resulting liposomes was again determined.
The mean size of the liposomes remained under 1 mm. In
most cases the size remained below 800 nm.
Protein thiolation. An antibody solution was prepared by
dissolving the protein in 0.1 mol/L phosphate buffer (pH
7.4) at a concentration of 5 mg ml21. A 20-mmol/ml21
solution of SPDP in ethanol was prepared. The SPDP
solution was added to the stirred protein solution to give a
molar ratio of SPDP to protein of 15:1. The mixture reacted
for 30 min at room temperature. After reaction, the protein
was separated from the reactants by gel chromatography.
The column was packed with Sephadex G-50 and equili-
brated with 0.05 mol/L sodium citrate, 0.05 mol/L sodium
phosphate and 0.05 mol/L sodium chloride at pH 7.0.
Detection of protein in column elutions was determined by
absorbance at 280 nm.
Reduction of derivatized protein. The pyridyl dithio-
protein solution was titrated in citrate–phosphate buffer to
pH 5.5 by addition of 1 mol/L HCl. A solution of
2.5 mol/L DTT in 0.2 mol/L acetate buffer, pH 5.5, was
made. Ten microliters of DTT solution was added for every
milliliter of protein solution. This mixture was allowed to
stand for 30 min. The protein was then separated from the
DTT by chromatography on a Sephadex G-50 column
Abbreviations and Acronyms
ATH 5 atherosclerosis




ICAM-1 5 intercellular adhesion molecule-1
MPB-PE 5 maleimido-4 (p-phenylbutyrate)-
phosphatidylethanolamine
PC 5 phosphatidylcholine
SPDP 5 3-(2-pyridyldithiolpropionic acid
N-hydroxysuccinimide ester
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equilibrated with citrate–phosphate buffer at pH 7.0. De-
tection of protein in the elution was determined by absor-
bance at 280 nm. Argon was bubbled through all buffers to
remove oxygen.
Conjugation of protein to liposomes. The protein was
mixed with the MPB-PE–containing liposomes and al-
lowed to react overnight under argon. Unbound protein was
separated from the liposomes on a Sepharose 4B column.
Detection of protein was determined by use of a bicincho-
ninic acid (BCA) protein assay (Pierce Labs, Rockford,
Illinois).
Size Measurements
The mean size of the liposomes was determined by
quasielastic light scattering measurements using a Nicomp
model 270 submicron particle sizer (Pacific Scientific,
Menlo Park, CA) equipped with a 5-mW helium–neon
laser at an exciting wavelength of 632.8 nm and with a
64-channel autocorrelation function, a temperature-
controlled scattering cell holder and an ADM 11 video
display terminal computer (Lear Siegler Inc., Anaheim,
California) for analyzing the fluctuations in scattered light
intensity generated by the diffusion of particles in solution.
The mean hydrodynamic particle diameter, dh, was ob-
tained from the Stokes–Einstein relation using the mea-
sured diffusion coefficient obtained from the fit.
Imaging
Liposomes were imaged with a 20-MHz high frequency
intravascular imaging catheter (Boston Scientific, Sunny-
vale, California) and a 7.5-MHz transvascular linear probe
(Acuson Inc., Mountain View, California). Instrument
settings for gain, zoom, compression and rejection levels
were optimized at the initiation of the experiment. To
correct for any minor variation in gain that may have
occurred throughout the image, the image data were scaled
to a common reference feature (see following section).
Images were recorded on to 1⁄2-in. VHS videotape in real
time for subsequent playback and image analysis.
Videodensitometric Analysis of Liposome “Brightness”
Relative echogenicity (apparent brightness) of all liposome
formulations was objectively assessed via computer-assisted
videodensitometry. This process involved image acquisition,
preprocessing, liposome identification and gray scale quan-
tification. All image processing and analysis was performed
with Image Pro Plus Software (version 1.0, Media Cyber-
netics, Silver Spring, Maryland) running on a dedicated
computer (486 CPU, 66 MHz). Images were digitized to
640 3 480 pixels spatial resolution (approximately 0.045
mm/pixel) and 8-bit (256 levels) amplitude resolution. The
distribution of gray scale values within the image was
adjusted to cover the entire range of possible gray levels
using a linear transformation algorithm (i.e., dynamic range
was maximized). Image brightness was scaled to a reference
feature, the annotation text, common to each image, retain-
ing a constant gray scale value over all images. The reference
text was imprinted on each frame before imaging. Therefore
as image gain and contrast were altered, the text image and
gain were altered to the same extent. An automated lipo-
some detection routine was run to identify liposomes within
a region of interest that encompassed the entire portion of
the artery visualized (Fig. 1). The automated liposome
detection routine identified and outlined all “bright” objects
within the analysis region having a gray scale level .29, a
roundness ratio (ratio of maximum diameter:minimum
diameter) ,2.5 and a size .4 pixels to avoid artifact. A
brightness area product (BAP) was calculated for each
complex. Brightness area products were generally in the
order of 500 to 5,000 units. Larger BAPs, compatible with
image artifact, primarily from the intravascular ultrasound
catheter, were highlighted and removed from image analy-
sis. This leaves some of the larger liposomal complexes
uncounted but insures that artifacts will not be part of the
liposomal analysis algorithm. Thus, objects identified were
considered to be “liposomes.” Areas of liposomes were
then numbered by the computer program, and the aver-
age gray scale and size of liposome groups were quanti-
fied. Liposomes/liposomal complexes are much smaller
than the imaging pixels, so detected liposomes will
appear larger than they actually are. When conjugated
Figure 1. This figure illustrates liposomes suspended in a glass vial prior to (left) and after (right) the videodensitometry program to assess
apparent brightness (see text for details).
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liposomes attach to the target site they further aggregate,
resulting in groups of liposomes contributing to each
detected bright complex.
Animal Studies
A standard Yucatan miniswine model of induced ATH was
developed to evaluate in vivo enhancement of ultrasonic
imaging of atheromas with the antibody-conjugated lipo-
somes. Atherosclerosis was developed by endothelial de-
nudement of one carotid and one iliofemoral artery under
chronic sterile conditions and ingestion of a markedly
hypercholesterolemic diet (21,22). After two weeks of feed-
ing, each animal was anesthetized and underwent percuta-
neous angioplasty to denude the endothelium of one carotid
and one iliofemoral artery. This allows active plaque devel-
opment consisting of fibrous and fatty tissue, and active
endothelial components. Four to six weeks later, after
transvascular ultrasound demonstrated active plaque, the
animal was anesthetized and artificially ventilated. Sheaths
were inserted into the femoral and carotid arteries for
vascular access and intravascular imaging catheter insertion.
Under stable conditions either intravascular or transvascular
imaging was performed. For intravascular imaging the
catheters were inserted close to the region of interest. For
transvascular imaging the transducer was placed over the
artery to be examined. For the antifibrinogen-conjugated
liposomal experiments, the animals were not heparinized for
2 h before imaging, allowing thrombus to form in the
peripheral arteries. The miniswine in the anti–ICAM-1
studies were kept on heparin throughout the experiment to
prevent thrombus formation. A total of 20 diseased arteries
in 10 pigs were prepared and used for these experiments; six
pigs for antifibrinogen experiments and four pigs for anti–
ICAM-1 experiments.
Baseline imaging of the artery and luminal blood was
performed, and images were recorded onto videotape. The
arteries were then imaged after one local injection each of
4 cc of agitated saline, 4 cc unconjugated liposomes and 4 cc
antibody-conjugated liposomes. Local injections were made
into both the normal and diseased carotid and femoral
arteries upstream of the intended target. The liposomes
were not allowed to incubate, and blood was flowing
through the arteries throughout the entire experiment.
Arteries were imaged for up to five min after injection of
saline and unconjugated liposomes, and up to 15 min after
injection of conjugated liposomes. The images were ana-
lyzed to determine acoustic enhancement of both unconju-
gated and conjugated liposomes as compared to blood pool
intensity. The mean gray scale of the liposomes was deter-
mined by averaging the values obtained from three image
frames for each arterial segment.
Statistical Analysis
Data were compared by analysis of variance and determined
to be statistically different at p , 0.05. All pairwise
comparisons were based on Tukey’s method for multiple
comparisons. All data are reported as mean 6 standard
deviation.
RESULTS
Imaging demonstrated visual enhancement of thrombus and
early stage atheroma with both sets of liposomes. The mean
size of both the conjugated and unconjugated liposomes
ranged from 0.5 mm to 1.0 mm consistently with an average
size of 0.8 mm. We have previously demonstrated that
conjugation does not affect the size of the liposomes (17).
Figure 2 illustrates imaging of thrombus with intravascular
ultrasound. Agitated saline injection produced transient
enhancement of the lumen. Similarly unconjugated lipo-
somes could be seen transiently during injection, but there
was no attachment to the thrombi or vessel wall. Figure 2,B
provides a negative control demonstrating that unconju-
gated liposomes did not attach to the thrombi after injec-
tion. The antifibrinogen liposomes, however, attached to
the thrombi after injection and enhanced the image at the
target site (Fig. 2,C). In real time these highly acoustic
liposomes attached to the plaque with marked acoustic
enhancement and shadowing of intraluminal blood. Figure
3 illustrates transvascular ultrasound images of the carotid
artery of a miniswine before and after injection of the
antifibrinogen liposomes. Here intraluminal thrombus was
not present, but the liposomes attached to the atheroscle-
rotic arterial wall—presumably at sites of exposed fibrin.
Transvascular imaging for 15 min demonstrated ongoing
acoustic enhancement.
Arteries were imaged by intravascular and transvascular
ultrasound after injection of saline, unconjugated liposomes
and the anti–ICAM-1 liposomes. Figure 4 illustrates the
femoral artery of a miniswine imaged with an intravascular
ultrasound catheter. After injection of unconjugated lipo-
somes, some liposomes can be seen in the lumen of the
artery, but none adhere to the arterial wall (Fig. 4,B). The
anti–ICAM-1 liposomes are attached directly to the endo-
thelial surface of the vessel wall (Fig. 4,C). The transvascu-
lar ultrasound images from the carotid artery of a miniswine
after injection of saline, unconjugated liposomes and anti–
ICAM-1 liposomes are illustrated in Figure 5. The anti–
ICAM-1 conjugated liposomes can be seen attached to the
lesion (Fig. 5,C), whereas the liposomes without antibody
are seen only in the lumen (Fig. 5,B).
All images were analyzed to measure acoustic reflectivity
of liposomes, agitated saline and blood components. Gray
scale values were determined for both the intravascular and
the transvascular images. The mean gray scale values of the
attached liposomes did not differ over time. Figure 6
demonstrates gray scale values for the intravascular images
and shows that there is no difference between the unconju-
gated (112 6 9.8) and conjugated (109 6 1.3) (gray scale;
mean 6 SD) liposomes, but both are brighter than the
agitated saline (73 6 4.6) and blood (37 6 7.2) (n 5 3
arterial segments per data set; three image frames per
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arterial segment) (see Tables 1 to 3 for data to Figs. 6 and
7). Similar results were seen for the transvascular imaging as
illustrated in Figure 7 (n 5 5 arterial segments per data set;
three image frames per arterial segment). The unconjugated
(83 6 2.3) and conjugated (81 6 3.6) (gray scale; mean 6
SD) liposomes were brighter than the agitated saline (59 6
4.0) and blood (29 6 2.2).
These results highlight the effectiveness of our formula-
tion as an acoustic contrast agent able to successfully target
pathologic tissues after in vivo injection.
DISCUSSION
Liposomes as acoustic contrast agents. To improve image
resolution, ultrasonic contrast agents have been employed.
Many contrast agents are being developed to enhance the
circulating blood pool and provide contrast between the
blood and the surrounding tissues. There are several diffi-
culties associated with the present contrast agents. One
common problem with gas-containing agents is the control
of the size and stability of the gas bubbles after injection.
Those that are too large will have difficulty passing through
the pulmonary capillary system. Encapsulated systems (mi-
crospheres) improve the stability of the systems, but not to
the desired extent. The half-life of the microspheres when
injected into the blood has been shown to be very short (less
than 1 min), due to uptake by the reticuloendothelial system
(23). Although many of these contrast agents may enhance
the circulating blood pool, thereby improving image reso-
Figure 2. Intravascular ultrasound images of the right femoral
artery of a Yucatan miniswine with a large central thrombus. (A)
After injection of saline. (B) After injection of unconjugated
liposomes. (C) After injection of antifibrinogen-labeled liposomes.
(The dark central area is catheter imaging artifact. C 5 intralu-
minal thrombus/clot; arrows point to liposomes attached to
thrombus.)
Figure 3. Transvascular ultrasound images of an atherosclerotic
left carotid artery of a Yucatan miniswine. (A) After injection of
saline. (B) After injection of antifibrinogen-labeled liposomes
(arrows point to liposomal attachment to fibrinogen in the
atherosclerotic plaque).
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lution, they do not provide site-specific enhancement of
structural pathology.
Acoustically reflective liposomes have many advantages
over other contrast agents. Liposomes, composed of phos-
pholipid bilayers, have been shown to be safe and efficacious
for use (24). Not all liposomes are reflective. Our liposomes
are acoustic solely by their lipid composition and method of
production (16). These changes in methodology of liposo-
mal formulation are important. The production method and
composition results in liposomes that are composed of many
well separated bilayers. We have previously shown that the
lipid composition greatly affects the reflectivity of the
liposomes. We have also shown that liposomes of this
formulation and resultant structure are highly reflective, but
liposomes composed of different formulations with resultant
single bilayer, unilamellar vesicles, are not (16). Mecha-
nisms of acoustic enhancement of our formulation include a
combination of membrane separation, number of mem-
branes, thickness and possibly air entrapment between
bilayers during the lyophilization process.
Additional advantages of our formulation include their
reproducibly small size (less than 1 mm), allowing them to
pass easily through the pulmonary circulation. The bilayer
phospholipids can be utilized for coupling molecules to the
external portion of the vesicle. We have shown that by
coupling antibodies to the surface, these liposomes can
target specific molecules (17). If conjugated to site-specific
antibodies, then both conjugated and unconjugated lipo-
somes would be applicable for systemic injection, delivery
and targeting. Our data demonstrate that the mean gray
scale of antifibrinogen liposomes attached to fibrous ather-
Figure 4. Similar to Figure 2, this illustrates intravascular ultra-
sound images of the atherosclerotic left carotid artery of a Yucatan
miniswine (notice the circular atheroma deposition). (A) After
injection of saline (arrows point to early atheroma). (B) After
injection of unconjugated liposomes (arrows point to liposomes
within the lumen). (C) After injection of anti–ICAM-1 labeled
liposomes (arrows point to liposomes attached to the atheroscle-
rotic plaque).
Figure 5. Similar to Figure 3, this illustrates transvascular ultra-
sound images of the atherosclerotic left carotid artery of a Yucatan
miniswine. (A) After injection of saline. (B) After injection of
unconjugated liposomes (arrows point to liposomes within the
lumen). (C) After injection of anti–ICAM-1 labeled liposomes
(arrows point to liposomes attached to the atherosclerotic plaque).
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oma initially was the same as the mean gray scale of the
same liposomes after 15 min in vivo.
Target-specific enhancement. We have demonstrated the
ability of these liposomes to target thrombi and atheroscle-
rotic plaques in an animal model of atherosclerosis. By
changing the antibody on the surface, the liposomes can
target different structures and may enhance the diagnostic
differentiation of plaque morphologic characteristics. This
may aid in tailoring therapy to atheroma at various stages of
plaque development. Identifying topographical and surface
features can help decide if drug therapy or mechanical
therapy would be more appropriate. Incorporation of
thrombolytic drugs into these liposomes for delivery to the
diseased tissue is a potential future use. Although this
system may have to be injected near the site of interest,
targeted liposomes could be injected intravenously if they
were conjugated to a ligand that is present only on athero-
sclerotic plaques.
There are currently no targeted ultrasound contrast
agents commercially available. A few other groups, however,
have begun investigation into the area. A biotinylated,
lipid-coated, perfluorocarbon emulsion that can target
thrombi is in development (25). This system, however,
involves a three-step targeting approach in which a biotin-
ylated ligand, avidin, and the biotinylated perfluorocarbon
emulsion particle must each reach the target to be effective.
Preliminary studies have shown enhancement of the target
only when the area of interest has first been incubated with
the first two steps in situ. Our system allows for injection
through the imaging catheter for immediate enhancement
without incubation or additional injections. Targeting of
perfluorobutane-gas–filled lipid microspheres to thrombi
has been demonstrated in preliminary in vitro studies (26).
Our study demonstrates the ability of antibody-conjugated
Figure 6. Gray scale values of antibody-conjugated liposomes
(Conj Lip), unconjugated liposomes (Unconj Lip), agitated saline
and blood during intravascular ultrasound imaging. The liposomes
are brighter than saline and blood as determined by analysis of
variance (p , 0.05).
Table 1. Mean Gray Scale Values
Blood Saline UnConj Conj
IVUS
45.24 77.69 121.09 109.95
31.08 71.84 112.65 109.01
35.76 68.69 101.55 107.41
TVUS
26.49 58.03 79.95 75.04
29.31 54.41 83.18 82.89
32.01 64.36 82.53 84.34
30.08 55.91 81.99 81.93
27.27 61.03 86.40 79.75
Conj 5 conjugated liposomes; IVUS 5 intravascular ultrasound; TVUS 5 transvas-
cular ultrasound; UnConj 5 unconjugated liposomes.







Group Mean SD SEM
IVUS-blood 37.360 7.214 4.165
IVUS-saline 72.740 4.567 2.637
IVUS-UnConj 111.763 9.800 5.658
IVUS-Conj 108.790 1.284 0.741
Source of
Variation df SS MS F p
Between
treatments
3 11,040.832 3,680.277 86.292 , 0.001
Residual 8 341.191 42.649
Total 11 11,382.023
All Pairwise Multiple Comparison Procedures
(Tukey Test) (Comparisons for Factor)
Comparison
Difference
of Means p q p < 0.05
IVUS-UnConj vs. IVUS-blood 74.403 4 19.733 Yes
IVUS-UnConj vs. IVUS-saline 39.023 4 10.350 Yes
IVUS-UnConj vs. IVUS-Conj 2.973 4 0.789 No
IVUS-Conj vs. IVUS-blood 71.430 4 18.945 Yes
IVUS-Conj vs. IVUS-saline 36.050 4 9.561 Yes
IVUS-Saline vs. IVUS-blood 35.380 4 9.383 Yes
One way analysis of variance. Data source: Data 1 in Notebook. Normality test:
passed (p 5 0.335). Equal variance test: passed (p 5 0.65). Power of performed test
with alpha 5 0.050:1.000. The differences in the mean values among the treatment
groups are greater than would be expected by chance; there is a statistically significant
difference (p # 0.001). Abbreviations as in Table 1.
MS 5 means squares; SS 5 sum of square.
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liposomes to target thrombi and atheroma in an animal
model under constant blood flow after local injection.
Factors influencing our results. Our liposomes visually
remained reflective for up to 15 min with transvascular
imaging. We have previously demonstrated and reported in
vivo retention of acoustic properties in solution for greater
than 15 days and as a freeze-dried powder with subsequent
reconstitution into solution for greater than 9 weeks. We
have not yet performed a systematic study to determine the
duration of acoustic properties in vivo. The exact concen-
tration and methods of injection for maximum acoustic
efficacy remain to be determined. Methods to make these
liposomes for sterile injection have yet to be developed.
Implications of our data. The implications of these pre-
liminary data are far reaching. These liposomes have the
potential to be conjugated to a variety of proteins that can
target various molecules and aid in the diagnosis and
characterization of many pathologies. This system also has
the potential for drug delivery to the target site. Although
these liposomes have not been loaded with drugs, the use of
liposomes as drug carriers has been widely described in
literature (27). As this liposomal formulation is inherently
acoustic and contain no gas, loading them with pharmaceu-
tical agents is feasible. Either hydrophilic or lipophilic drugs
could be encapsulated into the liposomes, and targeted to
specific tissues through the coupling of antibodies, or other
suitable molecules, to the outside of the liposomes. Our lab
is currently performing DNA transfer with antibody-
conjugated liposomes (28). These acoustic liposomes may
therefore serve in the future for both detection and treat-
ment of atheroma.
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MS 5 mean squares; SS 5 sum of squares.
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